|
US5461072A
|
|
Use of aryl hydroxyurea compounds for the treatment of atherosclerosis
|
|
US5403934A
|
|
Heterocyclic compounds
|
|
AU7244894A
|
|
Immunoreactive reagents employing monoamine oxidase
|
|
AU6402594A
|
|
Tumor targeting with l-enantiomeric oligonucleotide conjugates of immunoreagents and of chelated radionuclides
|
|
WO9416741A1
|
|
Immunoreactive reagents employing heterodimers
|
|
US5399580A
|
|
Therapeutic nucleosides-uses
|
|
US5290770A
|
|
Synergistic compositions
|
|
US5358970A
|
|
Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
|
|
US5512269A
|
|
Method of treating retained pulmonary secretions
|
|
US5342616A
|
|
Method of administering tissue plasminogen activator
|
|
US5290814A
|
|
Anti-atherosclerotic diaryl compounds
|
|
US5420115A
|
|
Method for the treatment of protoza infections with 21 -deoxy-21 -fluoropurine nucleosides
|
|
US5453510A
|
|
Neuromuscular blocking agents
|
|
US5208238A
|
|
Agents for potentiating the effects of antitumor agents and combating multiple drug resistance
|
|
US5240937A
|
|
Pharmaceutically active triazolopyridine compounds
|
|
US5405851A
|
|
Pharmaceutical compounds
|
|
US5207220A
|
|
Method for administering pharmaceuticals, including liquid surfactant, to the lungs
|
|
US5237052A
|
|
Antigenic preparations and isolation of such preparations
|
|
US5229122A
|
|
Pesticidal compositions
|
|
US5194450A
|
|
Anti-hypertensive sulfonanilides
|
